Abstract 4139207: Supraselective Administration of Very Low-dose Intracoronary Epinephrine as a Rescue and First-line Drug for the Management of No-reflow in Conjunction With the IIB-IIIA Inhibitor Tirofiban.
Circulation
NOVEMBER 11, 2024
to 10% of percutaneous coronary interventions (PCI), no-reflow is a complication associated with poor outcomes like myocardial infarction extension and death. However, one patient with LVEF 20% died of pulmonary edema 7 hours postangioplasty. Circulation, Volume 150, Issue Suppl_1 , Page A4139207-A4139207, November 12, 2024.
Let's personalize your content